News & Insights

As evidence teams plan for 2026, expectations in rare diseases are shifting towards evidence that is carefully contextualised and clearly linked to decision-making needs. Recent guidance and industry commentary highlight the growing role of patient experience data, integrated real-world evidence, and earlier cross-functional planning, reinforcing that credibility comes from clarity and relevance rather than scale or complexity alone.

DHT.health launch Evidence and Insights programmes, a multi-country initiative built to capture patient voice, lived experience and outcomes in rare and underserved diseases.

DHT.health recognised among Grant Thornton’s Top 100 “Ones to Watch” in the UK Pharma Services Sector

At DHT.health, we are proud to have contributed to Underserved, Overlooked: How our health systems are failing women and girls with a bleeding disorder, a powerful new report published by The Haemophilia Society (THS) which was presented to UK National Health Service leaders, Members of Parliament and broader stakeholders July 2025.

Patient Reported Outcomes in understanding lived experiences of individuals with a health condition.

Patient-Generated Data and Preferences in Europe's evolving HTA landscape.

In the rapidly evolving landscape of healthcare, patient-centricity is more than just a buzzword—it's becoming the cornerstone of...

The U.S. Food and Drug Administration (FDA) is setting a new standard for patient-centred care with its recently updated draft guidance...

Sickle cell disease (SCD) is a devasting genetic disorder. This article looks at the economic impact of SCD in Sub-Saharan Africa.